NCT06479863View on ClinicalTrials.gov

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 8, 2024

Primary Completion Date

May 30, 2027

Study Completion Date

August 30, 2027

Conditions
Sporadic Inclusion Body Myositis (sIBM)Idiopathic Inflammatory Myopathies
Interventions
COMBINATION_PRODUCT

Pozelimab/Cemdisiran

Patients to receive Pozelimab 200mg/Cemdisiran 200 mg SC injections every 4 weeks for 104 weeks

Trial Locations (2)

78759

RECRUITING

Austin Neuromuscular Center, Austin

RECRUITING

Austin Neuromuscular Center, Austin

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Austin Neuromuscular Center

OTHER